Home
Resources
Publications
Alzheimer's Disease and Its Potential Alternative Therapeutics

Alzheimer's Disease and Its Potential Alternative Therapeutics

Brent Kisby, Juliet T Jarrell, M Enes Agar, David S Cohen, Eric R Rosin, Catherine M Cahill, Jack T Rogers, Xudong Huang

J Alzheimers Dis Parkinsonism. 2019;9(5):477.

PMID: 31588368

Abstract:

Alzheimer's Disease (AD) is a chronic neurodegenerative disease that affects over 5 million individuals in the United States alone. Currently, there are only two kinds of pharmacological interventions available for symptomatic relief of AD; Acetyl Cholinesterase Inhibitors (AChEI) and N-methyl-D-aspartic Acid (NMDA) receptor antagonists and these drugs do not slow down or stop the progression of the disease. Several molecular targets have been implicated in the pathophysiology of AD, such as the tau (τ) protein, Amyloid-beta (Aβ), the Amyloid Precursor Protein (APP) and more and several responses have also been observed in the advancement of the disease, such as reduced neurogenesis, neuroinflammation, oxidative stress and iron overload. In this review, we discuss general features of AD and several small molecules across different experimental AD drug classes that have been studied for their effects in the context of the molecular targets and responses associated with the AD progression. These drugs include: Paroxetine, Desferrioxamine (DFO), N-acetylcysteine (NAC), Posiphen/-(-)Phenserine, JTR-009, Carvedilol, LY450139, Intravenous immunoglobulin G 10%, Indomethacin and Lithium Carbonate (Li2CO3).

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP101246666	Phenserine		101246-66-6	Price
AP425386603	LY450139		425386-60-3	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: